Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02809534 | A Study of Anlotinib in Patients With Hepatocellular Carcinoma(ALTER0802) | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 |
| NCT02802540 | Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients | unknown | Phase 2 / Phase 3 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01576796 | Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer(RTEP-5) | unknown | Phase 2 | 75 | Centre Henri BecquerelOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02841228 | Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer | unknown | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00697333 | Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC(PET-Plan) | unknown | Phase 2 | 200 | Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGNOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00754078 | A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy | unknown | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02268747 | Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer | unknown | Phase 2 | 43 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT02820116 | The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation | unknown | Phase 2 | 67 | Beijing Haidian HospitalOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT01803503 | Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors | unknown | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02317471 | Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 45 | Chinese PLA General HospitalOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02787915 | DC1s-CTL Cellular Therapy for Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Xuzhou Medical UniversityOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02788058 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | unknown | Phase 2 | 76 | First People's Hospital of HangzhouOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02610556 | Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT02487017 | DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT02651441 | D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 1 / Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT02780778 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT01745445 | Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)(SCLC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02772107 | Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 132 | Chinese PLA General HospitalOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02774200 | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT02766348 | Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients | unknown | Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 9, 2016 | clinicaltrials |
| NCT02484339 | Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)(α-RT) | unknown | Phase 2 | 274 | University Hospital FreiburgOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02753140 | Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | unknown | Phase 2 | 60 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Apr 27, 2016 | clinicaltrials |
| NCT02072031 | Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） | unknown | Phase 2 | 133 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2016 | clinicaltrials |
| NCT01149161 | Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma | unknown | Phase 2 / Phase 3 | 2,000 | Samsung Medical CenterOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02739204 | Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma | unknown | Phase 2 | 270 | China Medical University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02738723 | SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC | unknown | Phase 2 | 50 | Third Military Medical UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT02738983 | RT Plus EGFR-TKI for Wild-type NSCLC | unknown | Phase 2 | 22 | Hangzhou Cancer HospitalOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT02733107 | The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 25 | Third Military Medical UniversityOTHER | 1 | Apr 12, 2016 | clinicaltrials |
| NCT00690963 | Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating | unknown | Phase 1 / Phase 2 | 12 | AHS Cancer Control AlbertaOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01977235 | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer(TDICC) | unknown | Phase 2 | 110 | Third Military Medical UniversityOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02702323 | Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | unknown | Phase 2 / Phase 3 | 40 | Zhejiang Cancer HospitalOTHER | 0 | Mar 8, 2016 | clinicaltrials |
| NCT02398552 | A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. | unknown | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT02037997 | Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC | unknown | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT02688673 | DC Vaccine Combined With CIK Cells in Patients With SCLC | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT01924156 | DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT01784107 | A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 45 | Gachon University Gil Medical CenterOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT02672488 | Metformin Plus Sorafenib for Advanced HCC | unknown | Phase 2 | 82 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT02669719 | Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC | unknown | Phase 2 | 70 | Shanghai Chest HospitalOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02665702 | Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | unknown | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01900951 | Temozolomide as Maintenance Therapy in Small Cell Lung Cancer | unknown | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT02650544 | Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression | unknown | Phase 2 | 236 | Sun Yat-sen UniversityOTHER | 1 | Jan 8, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 7, 2016source: clinicaltrials